Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Easton, J. Jagers, M. Ji, K. Olson, M. Johnson, E. Wilde (Calgary, Canada; Uxbridge, United Kingdom). Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD. Eur Respir J 2014; 44: Suppl. 58, 4669

Member's Comments

No comment yet.

Related content which might interest you: Inhaled vilanterol trifenatate/fluticasone furoate increases maximum diaphragm contraction in severe COPD Source: International Congress 2014 – Clinical physiology and respiratory muscles Year: 2014 Effects of ciclesonide on the management of stable COPD with airway eosinophilia Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 First dose response to tiotropium in COPD: Impact on dyspnea, lung hyperinflation and distal airways Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on night-time and early morning symptoms in COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Inhaled vilanterol trifenatate/fluticasone furoate (VFF) improves respiratory muscle function and walking performance in severe COPD without change in pulmonary function Source: International Congress 2017 – Management of COPD Year: 2017 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014